Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Electroconvulsive Therapy01:30

Electroconvulsive Therapy

1.7K
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
1.7K
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

1.6K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.6K
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

1.1K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.1K
Depression: Overview01:18

Depression: Overview

1.1K
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
1.1K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

892
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
892
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

1.1K
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Resective temporal lobe surgery in refractory temporal lobe epilepsy: prognostic factors of postoperative seizure outcome.

Journal of neurosurgery·2026
Same author

T1w/T2w Ratio Identifies the Basolateral Amygdala as a Preferential Target in Autoimmune Limbic Encephalitis.

Journal of neuroimaging : official journal of the American Society of Neuroimaging·2026
Same author

Distinct neuronal populations in the human brain combine content and context.

Nature·2026
Same author

Phase of firing does not reflect temporal order in sequence memory of humans and recurrent neural networks.

Nature neuroscience·2025
Same author

Concept and location neurons in the human brain provide the 'what' and 'where' in memory formation.

Nature communications·2024
Same author

Long-term seizure outcome after epilepsy surgery of neuroglial tumors.

Frontiers in neurology·2024

Related Experiment Video

Updated: Mar 12, 2026

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.7K

Diagnosing and treating depression in epilepsy.

Christian E Elger1, Samantha A Johnston2, Christian Hoppe1

  • 1Department of Epileptology, University of Bonn Medical Centre, Sigmund-Freud-Strasse 25, FRG-53127 Bonn, Germany.

Seizure
|November 13, 2016
PubMed
Summary

Depression significantly impacts epilepsy patients, affecting emotional well-being. Early screening using tools like the NDDI-E and tailored treatments, including psychotherapy, are crucial for managing this common comorbidity.

Keywords:
Antidepressive drugsBurden of epilepsyDepression comorbidity in epilepsyDiagnosting depressive disordersEndogenous depressionPsychotherapy

More Related Videos

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
09:07

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

Published on: August 15, 2017

12.7K
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

29.8K

Related Experiment Videos

Last Updated: Mar 12, 2026

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.7K
Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
09:07

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

Published on: August 15, 2017

12.7K
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

29.8K

Area of Science:

  • Neurology
  • Psychiatry
  • Neuroscience

Background:

  • Epilepsy frequently co-occurs with depression, significantly impairing patients' emotional well-being.
  • At least one-third of epilepsy patients experience substantial emotional distress, necessitating targeted assessment.
  • The
  • burden of epilepsy
  • is a key factor, but neuroinflammation may also play a role.

Purpose of the Study:

  • To review the etiology and treatment of depression as a comorbidity of epilepsy.
  • To highlight the importance of screening and appropriate management strategies.
  • To advocate for a bio-psycho-social model in understanding and treating epilepsy-related depression.

Main Methods:

  • Literature review of studies on depression in epilepsy.
  • Analysis of screening instruments like the Neurological Disorders Depression Inventory for Epilepsy (NDDI-E).
  • Discussion of therapeutic approaches, including psychotherapy and pharmacotherapy.

Main Results:

  • Screening tools can identify patients needing support.
  • Psychotherapy is effective but underutilized; antidepressant efficacy is uncertain but modern agents may be safe.
  • Neurologists can manage mild/moderate cases, referring severe/complex cases to specialists.

Conclusions:

  • A bio-psycho-social model best explains depression in epilepsy.
  • Optimizing seizure control and managing antiepileptic drug side effects are primary treatment steps.
  • Timely identification and integrated care are essential for improving patient outcomes.